Developing medicines to protect healthy organs during cancer chemotherapy
Cisplatin treats several cancers but can damage hearing, kidneys and peripheral nerves. These effects can cause lasting disability and force clinicians to reduce doses or stop treatment, creating a difficult trade-off between controlling the cancer and protecting healthy organs.
Aegis Bio is developing medicines to reduce the toxic effects of cisplatin chemotherapy. Its preclinical approach aims to protect healthy organs while preserving anticancer activity, helping patients tolerate treatment and maintain effective dosing.
What stands out about Aegis Bio
Aegis Bio reports hearing protection and kidney-protective activity in animal studies of its cisplatin-supportive programme.
Aegis Bio was named an i-Lab 2026 laureate for its preclinical chemotherapy-protection programme in September 2026.
Co-founder Frédéric Venail spent ten years as Professor of Otolaryngology at Montpellier’s university and hospital.
Co-founder Jing Wang led hearing-disorder research as an INSERM Research Director and authored 60+ scientific publications. Co-founder Chames Kermi was a Stanford postdoctoral fellow.
Aegis Bio was created from Jing Wang’s Audisens-1 research project at the Montpellier Institute of Neuroscience, supported by SATT AxLR.
SATT AxLR selected Aegis Bio for its Time To Market Factory incubation programme in 2025 to support commercialisation and investor access.
Co-founder Frédéric Venail founded OTOINNOV, a hearing-care and research practice operating from August 2025, before Aegis Bio’s October 2025 formation.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.